TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 52.95

Change

0.00 (0.00)%

Market Cap

USD 2.02B

Volume

0.62M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 118.90B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 73.95B
ARGX argenx NV ADR

N/A

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 34.99B
ONC BeiGene, Ltd.

N/A

USD 25.62B
RPRX Royalty Pharma Plc

N/A

USD 18.12B
SMMT Summit Therapeutics PLC

N/A

USD 17.52B
UTHR United Therapeutics Corporatio..

N/A

USD 15.68B
INCY Incyte Corporation

N/A

USD 14.29B
INSM Insmed Inc

N/A

USD 13.70B

ETFs Containing TARS

BASE-B:CA Evolve Global Materials &.. 5.47 % 0.00 %

N/A

CAD 0.08B
SLX VanEck Steel ETF 5.26 % 0.56 %

N/A

N/A
XME SPDR® S&P Metals and Min.. 5.20 % 0.35 %

N/A

N/A
FXZ First Trust Materials Alp.. 4.86 % 0.64 %

N/A

N/A
PYZ Invesco DWA Basic Materia.. 3.71 % 0.60 %

N/A

USD 0.06B
SMLL Harbor ETF Trust 3.09 % 0.28 %

N/A

N/A
PICK iShares MSCI Global Metal.. 1.71 % 0.39 %

N/A

USD 0.31B
MDYV SPDR® S&P 400 Mid Cap Va.. 1.07 % 0.15 %

N/A

N/A
IVOV Vanguard S&P Mid-Cap 400 .. 1.02 % 0.20 %

N/A

USD 0.95B
FTA First Trust Large Cap Val.. 0.94 % 0.61 %

N/A

USD 1.21B
IWC iShares Micro-Cap ETF 0.48 % 0.60 %

N/A

N/A
FAB First Trust Multi Cap Val.. 0.47 % 0.70 %

N/A

USD 0.14B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.37% 50% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.37% 50% F 32% F
Trailing 12 Months  
Capital Gain 69.98% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.98% 87% B+ 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.68% 66% D+ 74% C
Dividend Return 20.68% 66% D+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.76% 52% F 29% F
Risk Adjusted Return 30.53% 85% B 62% D
Market Capitalization 2.02B 88% B+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector